20/20 Biolabs Inc (NASDAQ:AIDX – Get Free Report)’s stock price dropped 11.3% on Monday . The stock traded as low as $3.22 and last traded at $3.39. Approximately 338,540 shares changed hands during mid-day trading, a decline of 42% from the average daily volume of 583,018 shares. The stock had previously closed at $3.82.
20/20 Biolabs Stock Performance
20/20 Biolabs Company Profile
We develop and commercialize AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. We offer two families of lab tests, both under our OneTest brand: (i) OneTest for Cancer, a multi-cancer early detection, or MCED, blood test which has been our primary commercial focus and source of revenues since we wound down our COVID-19 testing business, and (ii) OneTest for Longevity, which measures inflammatory biomarkers, that we expect to launch in the first half of 2026.
See Also
- Five stocks we like better than 20/20 Biolabs
- CSE: ALEN.U is targeting a fast-growing digital wellness market
- New Copper-Rich “Kraken” Zone Discovered
- Your name isn’t on our protected list yet
- Elon Musk’s New 1,000X Opportunity
- Silver paying 20% dividend. Plus 68% share gains
Receive News & Ratings for 20/20 Biolabs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 20/20 Biolabs and related companies with MarketBeat.com's FREE daily email newsletter.
